Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg‐positive chronic hepatitis B: A five‐year observational cohort study
S.‐Y. Li; H. Li; Y.‐L. Xiong; F. Liu; M.‐L. Peng; D.‐Z. Zhang; H. Ren; P. Hu
Author Information: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education)
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.